Clough Capital Partners L P Buys Shares of 23,000 CRISPR Therapeutics AG $CRSP

Clough Capital Partners L P purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 23,000 shares of the company’s stock, valued at approximately $1,491,000.

Other large investors also recently modified their holdings of the company. Optiver Holding B.V. grew its holdings in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after acquiring an additional 210 shares during the period. Thompson Investment Management Inc. bought a new position in CRISPR Therapeutics in the third quarter valued at about $33,000. Bogart Wealth LLC boosted its position in CRISPR Therapeutics by 333.3% in the third quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock worth $42,000 after purchasing an additional 500 shares during the last quarter. Covestor Ltd purchased a new position in CRISPR Therapeutics in the third quarter worth about $48,000. Finally, Strategic Wealth Investment Group LLC bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at about $36,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, General Counsel James R. Kasinger sold 2,800 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total transaction of $147,840.00. Following the completion of the sale, the general counsel owned 87,815 shares in the company, valued at approximately $4,636,632. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total value of $517,334.40. Following the sale, the chief executive officer directly owned 235,558 shares in the company, valued at $12,437,462.40. This trade represents a 3.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 111,677 shares of company stock valued at $6,308,848 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY?2025 commercial progress: management reported $116M in FY?25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer?term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near?term EPS adjustments (slightly less negative for FY?2026/FY?2027), a modest constructive signal for near?term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most?searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short?interest data appears noisy: recent feeds show inconsistent/zero short?interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell?off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near?term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi?percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

CRISPR Therapeutics Stock Performance

CRSP opened at $48.75 on Friday. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.72. The firm’s fifty day moving average is $54.10 and its 200 day moving average is $57.26. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same quarter in the previous year, the company posted ($1.01) EPS. The company’s quarterly revenue was down 97.8% on a year-over-year basis. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CRSP. Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Citizens Jmp cut their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research report on Friday, January 30th. Bank of America reduced their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Evercore reissued an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Finally, Needham & Company LLC upped their price target on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.